

08 Jan 2026
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2026/01/08/3215319/0/en/Reviva-Announces-Publication-on-Clinical-Vocal-Biomarker-Data-from-the-RECOVER-Phase-3-Clinical-Trial-of-Brilaroxazine-to-Treat-Negative-Symptoms-in-Schizophrenia.html

23 Dec 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/12/23/3209836/0/en/Reviva-Announces-Regulatory-Update-Regarding-the-Development-of-Brilaroxazine-for-the-Treatment-of-Schizophrenia.html

10 Nov 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/11/10/3184521/0/en/Reviva-Announces-Grant-of-European-Patent-Covering-Use-of-Brilaroxazine-for-the-Treatment-of-Pulmonary-Fibrosis.html

28 Oct 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/10/28/3175313/0/en/Reviva-to-Present-Negative-Symptom-Data-for-Brilaroxazine-in-Schizophrenia-from-the-Phase-3-RECOVER-Double-Blind-and-Open-Label-Extension-Trials-at-the-CNS-Summit-2025.html

02 Jun 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/06/02/3091710/0/en/Reviva-Announces-Positive-Full-Dataset-for-1-Year-Phase-3-RECOVER-Open-Label-Extension-Study-Evaluating-Brilaroxazine-in-Schizophrenia.html

24 Apr 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/04/24/3067346/0/en/Reviva-to-Present-Late-Breaking-Poster-on-the-RECOVER-Long-term-Open-Label-Extension-Trial-for-Brilaroxazine-in-Schizophrenia-at-the-2025-ASCP-Annual-Meeting.html